Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10687-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10687-1-AP, RRID:AB_2253772
- Product name
- RERG antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated RERG antibody (Cat. #10687-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL.
The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.
ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma.
MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Zhang X, Zhao P, Ma M, Wu H, Liu R, Liu Z, Cai Z, Liu M, Xie F, Ma X
Frontiers in medicine 2023;10:1168977
Frontiers in medicine 2023;10:1168977
The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.
Coillard L, Guaddachi F, Ralu M, Brabencova E, Garbar C, Bensussan A, Le Bras M, Lehmann-Che J, Jauliac S
Frontiers in oncology 2022;12:804868
Frontiers in oncology 2022;12:804868
ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma.
Xiong Y, Huang H, Chen S, Dai H, Zhang L
Oncology reports 2019 Feb;41(2):1160-1168
Oncology reports 2019 Feb;41(2):1160-1168
MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.
Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS, Gao HW, Yu CP
Oncotarget 2017 Apr 4;8(14):22443-22459
Oncotarget 2017 Apr 4;8(14):22443-22459
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO
Breast cancer research and treatment 2011 Jul;128(2):315-26
Breast cancer research and treatment 2011 Jul;128(2):315-26
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- MCF7 cells were subjected to SDS PAGE followed by western blot with 10687-1-AP(RERG antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 10687-1-AP(RERG antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The RERG antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human RERG. This antibody recognizes human, mouse antigen. The RERG antibody has been validated for the following applications: ELISA, WB, IHC analysis.